Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bisnorcymserine - Annovis Bio

Next Previous
Drug Profile

Bisnorcymserine - Annovis Bio

Alternative Names: ANVS-301; Bisnorcymcerine; BNC

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute on Aging; National Institutes of Health (USA)
  • Developer Annovis Bio; Cenomed BioSciences; National Institute on Aging; National Institutes of Health (USA)
  • Class Antidementias; Phenylcarbamates; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Butyrylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dementia
  • No development reported Alzheimer's disease
  • Discontinued Poisoning

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers) in USA (PO, Capsule)
  • 02 May 2024 Phase-I clinical trials in Dementia (PO) (Annovis Bio pipeline, May 2024)
  • 24 Apr 2022 Bisnorcymserine is still in phase I development in Alzheimer's disease (In the elderly, In volunteers) in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top